Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million

Reuters

03/27

Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million

iMDx published a shareholder letter alongside its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of USD 4.1 million, up 115.8% year over year.
Fourth-quarter revenue was USD 1.1 million, with gross profit of USD 496,000 and gross margin of 43.5%.
Operating expenses in the quarter were USD 23.9 million, including USD 14.6 million of non-cash intangible asset impairment losses.
Net loss for the quarter was USD 23.0 million, or USD 0.72 per share, while adjusted net loss was USD 8.7 million, or USD 0.27 per share.
Management said it submitted the GraftAssureDx kidney transplant rejection test for FDA review and is planning for an FDA-authorized product this year, while guiding to average cash burn of about USD 7.5 million per quarter in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2622466896"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622466896\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622466896?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 04:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622466896","market":"fut","top_or_hot":-1,"title":"Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          iMDx published a shareholder letter alongside its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of USD 4.1 million, up 115.8% year over year.\n        </li>\n<li>\n          Fourth-quarter revenue was USD 1.1 million, with gross profit of USD 496,000 and gross margin of 43.5%.\n        </li>\n<li>\n          Operating expenses in the quarter were USD 23.9 million, including USD 14.6 million of non-cash intangible asset impairment losses.\n        </li>\n<li>\n          Net loss for the quarter was USD 23.0 million, or USD 0.72 per share, while adjusted net loss was USD 8.7 million, or USD 0.27 per share.\n        </li>\n<li>\n          Management said it submitted the GraftAssureDx kidney transplant rejection test for FDA review and is planning for an FDA-authorized product this year, while guiding to average cash burn of about USD 7.5 million per quarter in 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IMDX\">Insight Molecular Diagnostics Inc.</a> published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-03-27 04:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          iMDx published a shareholder letter alongside its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of USD 4.1 million, up 115.8% year over year.\n        </li>\n<li>\n          Fourth-quarter revenue was USD 1.1 million, with gross profit of USD 496,000 and gross margin of 43.5%.\n        </li>\n<li>\n          Operating expenses in the quarter were USD 23.9 million, including USD 14.6 million of non-cash intangible asset impairment losses.\n        </li>\n<li>\n          Net loss for the quarter was USD 23.0 million, or USD 0.72 per share, while adjusted net loss was USD 8.7 million, or USD 0.27 per share.\n        </li>\n<li>\n          Management said it submitted the GraftAssureDx kidney transplant rejection test for FDA review and is planning for an FDA-authorized product this year, while guiding to average cash burn of about USD 7.5 million per quarter in 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IMDX\">Insight Molecular Diagnostics Inc.</a> published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDIT","symbol_name":"Medite Cancer Diagnostics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL7Y4TcY:1","article_id":"2622466896","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622466896","pubTimestamp":1774555787,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"iMDx published a shareholder letter alongside its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of USD 4.1 million, up 115.8% year over year.Fourth-quarter revenue was USD 1.1 million, with gross profit of USD 496,000 and gross margin of 43.5%.Operating expenses in the quarter were USD 23.9 million, including USD 14.6 million of non-cash intangible asset impairment losses.Net loss for the quarter was USD 23.0 million, or USD 0.72 per share, while adjusted net loss was USD 8.7 million, or USD 0.27 per share.Management said it submitted the GraftAssureDx kidney transplant rejection test for FDA review and is planning for an FDA-authorized product this year, while guiding to average cash burn of about USD 7.5 million per quarter in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDIT":"Medite Cancer Diagnostics, Inc.","BK4082":"医疗保健设备","BK4139":"生物科技","IMDX":"Insight Molecular Diagnostics Inc."},"translate_title":"Insight Molecular Diagnostics 2025财年收入增长115.79%至410万美元；运营费用攀升37%至5,340万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMDX":0.9,"MDIT":0.9},"content_text":"Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million\n    \n\n\n          iMDx published a shareholder letter alongside its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of USD 4.1 million, up 115.8% year over year.\n        \n\n          Fourth-quarter revenue was USD 1.1 million, with gross profit of USD 496,000 and gross margin of 43.5%.\n        \n\n          Operating expenses in the quarter were USD 23.9 million, including USD 14.6 million of non-cash intangible asset impairment losses.\n        \n\n          Net loss for the quarter was USD 23.0 million, or USD 0.72 per share, while adjusted net loss was USD 8.7 million, or USD 0.27 per share.\n        \n\n          Management said it submitted the GraftAssureDx kidney transplant rejection test for FDA review and is planning for an FDA-authorized product this year, while guiding to average cash burn of about USD 7.5 million per quarter in 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}